Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), has been recommended for approval by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as a first-line treatment for advanced renal cell carcinoma (RCC).

The drug was also recommended for second-line treatment of adult patients with advanced kidney cancer who met certain criteria and had received one prior treatment with cytokine therapy (interleukin 2 or interferon).

Recommendations for marketing approval by the CHMP are normally endorsed by the European Commission within a couple of months.

Read more here